Bradley & Co Private Wealth Management’s Summit Therapeutics SMMT Stock Holding History

Bradley & Co Private Wealth Management’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-200	Closed	-$4.13K	–	226
2025 Q3	$4.13K	Hold	200	–	–	﹤0.01%	159
2025 Q2	$4.26K	Hold	200	–	–	﹤0.01%	150
2025 Q1	$3.86K	Hold	200	–	–	﹤0.01%	151
2024 Q4	$3.57K	Buy	+200	New	+$3.88K	﹤0.01%	150
2024 Q2	$1.56K	Hold	200	–	–	﹤0.01%	160
2024 Q1	$828	Hold	200	–	–	﹤0.01%	171
2023 Q4	$522	Hold	200	–	–	﹤0.01%	183
2023 Q3	$374	Hold	200	–	–	﹤0.01%	168
2023 Q2	$502	Hold	200	–	–	﹤0.01%	169
2023 Q1	$350	Hold	200	–	–	﹤0.01%	163
2022 Q4	$850	Hold	200	–	–	﹤0.01%	165
2022 Q3	$0	Hold	200	–	–	﹤0.01%	189
2022 Q2	$0	Hold	200	–	–	﹤0.01%	190
2022 Q1	$0	Hold	200	–	–	﹤0.01%	166
2021 Q4	$1K	Hold	200	–	–	﹤0.01%	159
2021 Q3	$1K	Hold	200	–	–	﹤0.01%	162
2021 Q2	$1K	Hold	200	–	–	﹤0.01%	166
2021 Q1	$1K	Buy	+200	New	+$1.29K	﹤0.01%	168

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

PCMH

Polymer Capital Management (HK) Hong Kong $1.98B AUM 210.13% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Bradley & Co Private Wealth Management's SMMT Position: Q4 2025 in Review

Bradley & Co Private Wealth Management sold out of Summit Therapeutics (SMMT) in Q4 2025, closing a stake of 200 shares — an estimated $4.13K sold.

Bradley & Co Private Wealth Management first reported a position in SMMT in Q1 2021 and held it in 18 quarters. The position peaked at $4.26K in Q2 2025. 206 funds tracked by Wall St. Rank hold SMMT as of Q4 2025.

Bradley & Co Private Wealth Management reported no remaining Summit Therapeutics position as of Q4 2025 after selling out during the quarter.
Bradley & Co Private Wealth Management sold 200 Summit Therapeutics shares in Q4 2025, an estimated $4.13K.
Bradley & Co Private Wealth Management first reported a position in Summit Therapeutics in Q1 2021 and held it in 18 quarters.
Bradley & Co Private Wealth Management's Summit Therapeutics position peaked at $4.26K in Q2 2025.
206 funds tracked by Wall St. Rank held Summit Therapeutics as of Q4 2025.

Based on Bradley & Co Private Wealth Management's 13F filing for Q4 2025, filed 11 Feb 2026.